## RESEARCH

## **Open Access**



Improvements in cholesterol efflux capacity of HDL and adiponectin contribute to mitigation in cardiovascular disease risk after bariatric surgery in a cohort with morbid obesity

Himani Thakkar<sup>1†</sup>, Vinnyfred Vincent<sup>1†</sup>, Sakshi Shukla<sup>1</sup>, Manraj Sra<sup>2</sup>, Uma Kanga<sup>3</sup>, Sandeep Aggarwal<sup>4</sup> and Archna Singh<sup>1\*</sup>

## Abstract

Background: Bariatric surgery can alleviate cardiovascular risk via effects on cardiovascular disease (CVD) risk factors such as diabetes mellitus, hypertension, and dyslipidemia. Our study aimed to assess the cholesterol efflux capacity (CEC) of HDL as a negative risk factor for CVD in individuals with obesity and identify the factors associated with improvement in CEC 3 months following bariatric surgery.

Methods: We recruited 40 control individuals (mean BMI of 22.2 kg/m<sup>2</sup>) and 56 obese individuals (mean BMI of 45.9 kg/m<sup>2</sup>). The biochemical parameters, inflammatory status and CEC of HDL was measured for the obese individuals before bariatric surgery and at 3 months after surgery. The CEC was measured using a cell-based cholesterol efflux system of BODIPY-cholesterol-labelled THP-1 macrophages.

**Results:** A significant reduction in BMI (-17%, p < 0.001), resolution of insulin sensitivity (HOMA2-IR = -23.4%, p = 0.002; Adipo IR = -16%, p = 0.009) and inflammation [log resistin = -6%, p = 0.07] were observed 3 months post-surgery. CEC significantly improved 3 months after surgery [Pre:  $0.91 \pm 0.13$ ; Post:  $1.02 \pm 0.16$ ; p = 0.001] despite a decrease in HDL-C levels. The change in CEC correlated with the change in apo A-I (r = 0.39, p = 0.02) and adiponectin levels (r = 0.35, p = 0.03).

**Conclusion:** The results suggest that improvements in CEC, through improvement in adipose tissue health in terms of adipokine secretion and insulin sensitivity could be an important pathway in modulating obesity-related CVD risk.

Keywords: Bariatric surgery, Cardiovascular risk, Dyslipidemia, Insulin resistance, Cholesterol efflux capacity, Adiponectin

\*Correspondence: arch\_singh@ymail.com

<sup>†</sup>Himani Thakkar and Vinnyfred Vincent contributed equally to this work <sup>1</sup> Department of Biochemistry, All India Institute of Medical Sciences, Room No. 3044, New Delhi 110029, India

Full list of author information is available at the end of the article

## 

Introduction

Cardiovascular disorders (CVD) account for about onethird of the global deaths. One of the modifiable risk factors for the development of CVD is obesity [1]. According to the World Health Organization, about 13% of the world's adult population in 2016 was plagued by obesity. The obesity-induced metabolic alterations predispose an

© The Author(s) 2021, corrected publication 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.